Cardio Diagnostics Holdings Inc
cdio.aiWhat Do They Do?
Sells cardiovascular blood tests and risk-information tools to clinicians, healthcare organizations and employers.
10-K for FY2025, filed Mar 13, 2026
How Do They Make Money?
The company earns money from cardiovascular tests: telemedicine providers and provider organizations are billed monthly for completed tests or accepted samples, while employers are billed after a heart-disease fair, sample acceptance, or completion of testing.
10-K for FY2025, filed Mar 13, 2026For telemedicine, the telemedicine provider collects payments from patients upon completion of eligibility screening and test order.…View ↗
For provider organizations, the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on the…View ↗
For employer organizations, the cost of each test is negotiated prior to testing commencing. Pricing is determined based largely on testing…View ↗
$14.8K
-
10-K for FY2025, filed Mar 13, 2026
$14.8K ↗
Who Are Their Customers?
The tests are offered through telemedicine providers, provider organizations such as concierge practices and longevity clinics, and employers; patients can also pay directly.
10-K for FY2025, filed Mar 13, 2026
Do Revenues Turn Into Profits?
No. It lost $6.5M in FY2025.
10-K for FY2025, filed Mar 13, 2026
−$6.5MView ↗
10-K for FY2025, filed Mar 13, 2026
−$6.5MView ↗
10-K for FY2025, filed Mar 13, 2026
−$5.9MView ↗
How Are They Changing?
Growing. Revenue grew 16.5x in 4 years, from $901 in FY2021 to $14.8K in FY2025, about 101% a year.
Broader customer channels
Earlier, the company described selling its test through telemedicine and shifting effort toward customer relationships; the latest report describes broader reach through provider organizations, channel partners, employers, payors and life insurers.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 13, 2026Our first test, Epi+Gen CHD™, which was introduced for market testing in 2021, is a three-year symptomatic CHD risk assessment test…View ↗
Cardio launched its first clinical test, Epi+Gen CHD™, a three-year symptomatic CHD risk assessment clinical blood test targeting CHD…View ↗
Expanded product range
The older report describes clinical tests for coronary heart disease; the latest also lists research tools for biopharmaceutical development and a cardiovascular risk-information platform.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 13, 2026Our first test, Epi+Gen CHD™, which was introduced for market testing in 2021, is a three-year symptomatic CHD risk assessment test…View ↗
Cardio launched its first clinical test, Epi+Gen CHD™, a three-year symptomatic CHD risk assessment clinical blood test targeting CHD…View ↗
Loading...
